1. Home
  2. SWKS vs CYTK Comparison

SWKS vs CYTK Comparison

Compare SWKS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skyworks Solutions Inc.

SWKS

Skyworks Solutions Inc.

HOLD

Current Price

$72.45

Market Cap

9.0B

Sector

Technology

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$78.78

Market Cap

10.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWKS
CYTK
Founded
1962
1997
Country
United States
United States
Employees
N/A
673
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
10.7B
IPO Year
1995
2004

Fundamental Metrics

Financial Performance
Metric
SWKS
CYTK
Price
$72.45
$78.78
Analyst Decision
Hold
Strong Buy
Analyst Count
15
19
Target Price
$70.38
$89.26
AVG Volume (30 Days)
4.6M
1.7M
Earning Date
05-05-2026
05-05-2026
Dividend Yield
4.53%
N/A
EPS Growth
N/A
N/A
EPS
0.76
N/A
Revenue
$4,086,900,000.00
$13,368,000.00
Revenue This Year
N/A
$7.37
Revenue Next Year
$3.06
$310.19
P/E Ratio
$95.30
N/A
Revenue Growth
N/A
N/A
52 Week Low
$51.93
$31.99
52 Week High
$90.90
$80.20

Technical Indicators

Market Signals
Indicator
SWKS
CYTK
Relative Strength Index (RSI) 49.54 63.90
Support Level $69.35 $59.07
Resistance Level $76.85 $79.66
Average True Range (ATR) 4.27 3.20
MACD -1.12 0.56
Stochastic Oscillator 28.47 89.87

Price Performance

Historical Comparison
SWKS
CYTK

About SWKS Skyworks Solutions Inc.

Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: